Preliminary evidence of bronchodilating activity of TPI 1020 (NO-budesonide) in humans

B. O‘Connor, M. Armogida, A. Raza (London, United Kingdom; Sophia Antipolis, France)

Source: Annual Congress 2006 - Novel treatments for asthma
Session: Novel treatments for asthma
Session type: Oral Presentation
Number: 751
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. O‘Connor, M. Armogida, A. Raza (London, United Kingdom; Sophia Antipolis, France). Preliminary evidence of bronchodilating activity of TPI 1020 (NO-budesonide) in humans. Eur Respir J 2006; 28: Suppl. 50, 751

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009


Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 147s
Year: 2001

The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003

Bronchoprotective activity and safety evaluation of the novel antimuscarinic/ß2 agonist (MABA) CHF6366 in dogs
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Advantageous toxicity profile of novel inhaled antisense oligonucleotides, TPI ASM8 and TPI 1100, following chronic dosing in monkeys
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008



Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016


AWD 12-281, a new selective PDE4-inhibitor with a high safety margin: separation of anti-inflammatory and emetic effects in ferrets and domestic pigs
Source: Eur Respir J 2002; 20: Suppl. 38, 617s
Year: 2002

Ovalbumin-induced asthma model in Brown Norway rats demonstrates potential anti-asthmatic effects of Neu-164, a novel antioxidant and anti-inflammatory compound
Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models
Year: 2008

Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects
Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases
Year: 2003


Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009

Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 353s
Year: 2007

Inhaled liposomal treprostinil (L606) shows extended release in healthy volunteer, as well as prolongs pharmacological effect in hypoxia-induced rat.
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020


Bronchoprotective activity of sildenafil (Viagra) in asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 429s
Year: 2001

Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro
Source: Eur Respir J 2002; 20: Suppl. 38, 91s
Year: 2002

Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014


Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

The influence of polymorphisms of the β2- adrenoceptor (AR) gene and the β2-AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001

Pharmacokinetics and pre-clinical efficacy of ralinepag (APD811) in humans and rats
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017




In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells
Source: Eur Respir J 2001; 18: Suppl. 33, 95s
Year: 2001